Comment

Comment by Dr. Krishna Kumari Challa on October 5, 2021 at 9:33am

2 win medicine Nobel for showing how we react to heat, touch

Two scientists won the Nobel Prize in medicine on Monday for their discoveries into how the human body perceives temperature and touch, revelations that could lead to new ways of treating pain or even heart disease.

 David Julius and Ardem Patapoutian separately identified receptors in the skin that respond to heat and pressure, and researchers are working on drugs to target them. Some hope the discoveries could eventually lead to pain treatments that reduce dependence on highly addictive opioids. 

Julius, of the University of California at San Francisco, used capsaicin, the active component in chili peppers, to help pinpoint the nerve sensors that respond to heat, the Nobel Committee said. Patapoutian, of Scripps Research Institute at La Jolla, California, found pressure-sensitive sensors in cells that respond to mechanical stimulation.

This really unlocks one of the secrets of nature. It's actually something that is crucial for our survival, so it's a very important and profound discovery.

Announcement of the 2021 Nobel Prize in Physiology or Medicine

https://medicalxpress.com/news/2021-10-nobel-prize-honors-discovery...

Comment by Dr. Krishna Kumari Challa on October 4, 2021 at 11:20am

The promise of medical science

Understanding and treating Necrotizing Enterocolitis in babies

Comment by Dr. Krishna Kumari Challa on October 3, 2021 at 1:55pm

Mystery of the Pulsating Spider

Comment by Dr. Krishna Kumari Challa on October 3, 2021 at 11:37am

Covid pill cuts hospitalizations by 50%

Oral drug molnupiravir for Covid-19 was shown to reduce the chance newly infected patients were hospitalized by 50 percent. A simple pill to treat the coronavirus has been sought since the start of the pandemic and Friday's announcement was hailed as a major step towards that goal.

In a late stage clinical trial, Merck and its partner Ridgeback Therapeutics evaluated data from 775 patients -- roughly half of whom received either a five-day course of the pill, while the other received a placebo.

All the patients had lab-confirmed Covid-19 with symptoms that developed within five days of them being assigned to their respective groups.

Of the patients who received molnupiravir, 7.3 percent were hospitalized by day 29, compared to 14.1 percent of those on a placebo -- a relative risk reduction of around 50 percent.

There were also eight deaths in the placebo group but, significantly, none in the drug group.

Efficacy was said to hold up against variants of concern, including Delta, and the drug had a good safety profile.

The results were compelling enough that an independent data monitoring committee in consultation with the FDA decided to halt the trial early, which could indicate they felt it would be unethical to continue with a placebo arm.

Molnupiravir belongs to a class of antiviral drugs called "polymerase inhibitors," which work by targeting an enzyme that viruses need to copy their genetic material, and introducing mutations that leave them unable to replicate.

Such drugs are expected to be more variant-proof than monoclonal antibody treatments, which target a surface protein of the virus that is continually evolving.

It was initially developed as an inhibitor of influenza and respiratory syncytial virus, two other important acute respiratory infections, by a team at Emory University.

"If it is proven to be very safe and proven to be effective, then it can be used broadly, irrespective of the diagnosis, to treat and prevent multiple respiratory infections.

But experts also cautioned they would like to see the complete underlying data. They also stress that this is no substitute for vaccination. It's not a miracle cure but a companion tool. And if the drug is used carelessly, the public may end up developing resistance to the drug.

Experts also said it would be crucial to administer the drug early. Since it isn't always clear who is at risk for developing severe disease, it would have the greatest impact if it is cheap enough to distribute widely.

https://researchnews.cc/news/9225/Merck-s-Covid-pill-hailed-after-c...

Comment by Dr. Krishna Kumari Challa on October 3, 2021 at 11:26am

Primordial 'hyper-eye' discovered

An international research team has found an eye system in trilobites of the suborder Phacopina from the Devonian (390 million years ago) that is unique in the animal kingdom: each of the about 200 lenses of a hyper-facet eye spans a group of six normal compound-eye-facets, forming a compound eye itself. In addition to the hyper-facetted eyes, the researchers identified a structure that they think to be a local neural network which directly processed the information from this special eye, and an optic nerve that carried information from the eye to the brain. The article, "A 390 million-year-old hyper-compound eye in Devonian phacopid trilobites," has been published in Scientific Reports.

B. Schoenemann, E. N. K. Clarkson, C. Bartels, W. Südkamp, G. E. Rössner, U. Ryck. A 390 million-year-old hyper-compound eye in Devonian phacopid trilobites. Scientific Reports, 2021; 11 (1) DOI: 10.1038/s41598-021-98740-z

https://www.sciencedaily.com/releases/2021/09/210930101416.htm

Comment by Dr. Krishna Kumari Challa on October 2, 2021 at 12:43pm

The Scientific Problem of Consciousness

Comment by Dr. Krishna Kumari Challa on October 2, 2021 at 12:28pm

During COVID-19, many hospitals find themselves short on ventilators. During the pandemic, many will require the use of a ventilator for an average of 15 days, while a few people will need significantly more time. Ventilators aren’t something that a person can use for one day and then get discharged. The first wave of people requiring ventilators will receive them immediately. However, someone whose lungs fail the next day may need to survive for two weeks without one.

https://next.massivesci.com/articles/rectal-breathing-oxygen-enema-...

Part 3

Comment by Dr. Krishna Kumari Challa on October 2, 2021 at 12:28pm

While we often consider the butt as the exit for waste in our body, it is also an entryway with lifesaving potential. After all, humans and plenty of other mammals can absorb medications rectally. That’s because there’s a lot of blood vessels in the area, allowing medicine easy entry. 

But medicine is specially designed to maximize absorption in the body. Oxygen doesn’t have nearly as easy a path towards entry into the bloodstream through the rectum because of the mucus membrane mammals have on the intestines. There are also important anatomical differences between our intestines and those of fish that already harness this ability. Animals that can breathe through their butts, like loaches, had a much thinner epithelium in their guts and a lot less mucus. During the course of early development, a butt-breathing genetic pathway is turned on that helps dictate the structure of the intestine. When it’s all said and done, the posterior end of the intestine is equipped with all the structures necessary for respiration (and gas exchange).

Would this mucus prevent oxygenation in mice? In the first experiment, researchers used a model of oxygen deprivation in mice, preventing them from breathing through their lungs. The control group didn’t receive any intestinal ventilation, one group received oxygen through an anal catheter, and the final group had the mucus layer on their intestines “scrubbed” before receiving anal ventilation.

Remarkably, the mice supplied oxygen through their anus had elevated oxygen levels in their blood. The final group that also had their intestinal mucus scrubbed fared even better, surviving the longest in the low-oxygen conditions — five times as long as the control group. This experiment proved that there is potential for mammals to breathe through their butt, however, the mucus layer covering the intestinal epithelial cells makes it more difficult.

In a clinical setting, scrubbing the mucus off of a person’s intestines isn’t really feasible, and doesn’t sound like a pleasant experience. But using a method akin to an enema may work, by infusing safe, oxygenated liquid through the butt. This liquid, called perfluorodecalin, could safely store and deliver oxygen via an enema. Due to the properties of this liquid, it doesn’t need to scrub the mucus off of the intestines, meaning less discomfort and abrasion. Oxygen diffuses into the bloodstream while carbon dioxide diffuses out. Since it holds a lot of oxygen and carbon dioxide very easily, it is also delivered safely to the lungs, and is already in clinical use. 

Part2

Comment by Dr. Krishna Kumari Challa on October 2, 2021 at 12:26pm

A breathing tube through the butt could be an alternative to mechanical ventilators

Inspired by animals that breathe through their butts, scientists show that mammals can also harness the incredible breathing ability of our butts.

To survive in extreme low-oxygen conditions deep in the ocean, fish and other creatures have developed remarkable adaptations. For example, sea spiders, loaches, and catfish evolved the ability to breathe through their butts. And they might not be the only butt breathers out there. 

A recent study in the journal Med now suggests that mammals, humans included, may be able to breathe through their rear ends as well. Mice, rats, and pigs could all stave off the devastating effects of oxygen deprivation if given an oxygen enema. But could this new method provide temporary oxygen while a patient awaits a ventilator?

Part1

Comment by Dr. Krishna Kumari Challa on October 2, 2021 at 9:27am

'Fight or flight' – unless internal clocks are disrupted, study in mice shows

For humans and animals, many aspects of normal behavior and physiology rely on the proper functioning of the body's circadian clocks.

Here's how it's supposed to work: Your brain sends signals to your body to release different hormones at certain times of the day. For example, you get a boost of the hormone cortisol—nature's built-in alarm system—right before you usually wake up.

But hormone release actually relies on the interconnected activity of clocks in more than one part of the brain. New research from Washington University in St. Louis shows how daily release of glucocorticoids depends on coordinated clock-gene and neuronal activity rhythms in neurons found in two parts of the hypothalamus, the suprachiasmatic nucleus (SCN) and paraventricular nucleus (PVN).

The new study, conducted with freely behaving mice, is published Oct. 1 in Nature Communications.

Normal behavior and physiology depends on a near 24-hour circadian release of various hormones. When hormone release is disrupted, it can lead to numerous pathologies, including affective disorders like anxiety and depression and metabolic disorders like diabetes and obesity.

The daily timing of hormone release is controlled by the SCN. Located in the hypothalamus, just above where the optic nerves cross, neurons in the SCN send daily signals that are decoded in other parts of the brain that talk to the adrenal glands and the body's endocrine system.

"Cortisol in humans (corticosterone in mice) is more typically known as a stress hormone involved in the 'fight or flight' response. But the stress of waking up and preparing for the day is one of the biggest regular stressors to the body. Having a huge amount of this glucocorticoid released right as you wake up seems to help you gear up for the day.

Circadian neurons in the paraventricular nucleus entrain and sustain daily rhythms in glucocorticoids, Nature Communications (2021). DOI: 10.1038/s41467-021-25959-9

https://phys.org/news/2021-10-flight-internal-clocks-disrupted-mice...

• ‹ Previous
• 1
• …
• 335
• 336
• 337
• 338
• 339
• …
• 849
• Next ›
• Page